Inloggen

Login
 
Wachtwoord vergeten?

Probiodrug 2019

Volgen
 
Klik hier om dit forumtopic te volgen en automatisch op de hoogte gehouden te worden bij nieuwe berichten.
3.114 Posts
Pagina: «« 1 ... 149 150 151 152 153 ... 156 »» | Laatste | Omlaag ↓
  1. forum rang 5 Gala-diner 26 augustus 2019 06:29
    quote:

    fly like an eagle schreef op 25 augustus 2019 12:12:


    15 M voor exclusieve rechten op de small molecules voor oncology door Morpho lijkt me geen geweldige deal maar geeft lucht aan Vivo om phase 2B proberen uit te voeren. heb ze al jaren als gok op 20 euro en moet het allemaal nog maar zien.

    Misschien moet je als aandeelhouder van Vivoryon de persberichten beter lezen.
    Er is alleen bekendgemaakt dat Morphosys de optie heeft op het gebruik van de Inhibitoren van Vivoryon en dat ze hebben toegezegd een aandelen belang in Vivoryon te nemen van 15 miljoen.
    Als ze de optie lichten dan zal Morphosys een entreefee betalen aan Vivoryon.
    Dat kon nog weleens meer dan 15 miljoen zijn.
    Daar komt bij dat ze dan milestoniebetalingen afspreken en de hoogte van de royalty's.
    Vivoryon heeft meer dan 60 verschillende Inhibitoren, je kan er dus vanuit gaan dat Vivoryon nog meer deals kan gaan afsluiten.
  2. Kuiken 26 augustus 2019 11:11
    quote:

    Gala-diner schreef op 26 augustus 2019 06:29:


    [...]
    Misschien moet je als aandeelhouder van Vivoryon de persberichten beter lezen.
    Er is alleen bekendgemaakt dat Morphosys de optie heeft op het gebruik van de Inhibitoren van Vivoryon en dat ze hebben toegezegd een aandelen belang in Vivoryon te nemen van 15 miljoen.
    Als ze de optie lichten dan zal Morphosys een entreefee betalen aan Vivoryon.
    Dat kon nog weleens meer dan 15 miljoen zijn.
    Daar komt bij dat ze dan milestoniebetalingen afspreken en de hoogte van de royalty's.
    Vivoryon heeft meer dan 60 verschillende Inhibitoren, je kan er dus vanuit gaan dat Vivoryon nog meer deals kan gaan afsluiten.


    During the option period, MorphoSys will conduct preclinical validation experiments on Vivoryon’s [family of QPCTL inhibitors, including an assessment of the potential benefits of combining them with MorphoSys’s proprietary program tafasitamab (MOR208), which is currently in late-stage development for the treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).


    Morphosys mag meerdere inhibitors testen, dat zal niet over één nacht ijs gaan.
  3. forum rang 5 Gala-diner 26 augustus 2019 11:26
    quote:

    Kuiken schreef op 26 augustus 2019 11:11:


    [...]

    During the option period, MorphoSys will conduct preclinical validation experiments on Vivoryon’s [family of QPCTL inhibitors, including an assessment of the potential benefits of combining them with MorphoSys’s proprietary program tafasitamab (MOR208), which is currently in late-stage development for the treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).


    Morphosys mag meerdere inhibitors testen, dat zal niet over één nacht ijs gaan.

    Slechts valideren kost niet zo enorm veel tijd, bovendien zal Morphosys ook haast willen maken.
    Valideren is iets anders dan testen...
    Dat testen mogen ze pas gaan doen als ze de optie lichten.
    Ik gok dat het maximaal nog een maand zal duren voordat Morphosys de optie licht.
  4. Kuiken 26 augustus 2019 12:03
    quote:

    Gala-diner schreef op 26 augustus 2019 11:26:


    [...]
    Slechts valideren kost niet zo enorm veel tijd, bovendien zal Morphosys ook haast willen maken.
    Valideren is iets anders dan testen...
    Dat testen mogen ze pas gaan doen als ze de optie lichten.
    Ik gok dat het maximaal nog een maand zal duren voordat Morphosys de optie licht.



    ok verhelderend.
  5. forum rang 5 Gala-diner 26 augustus 2019 14:41
    quote:

    DeZwarteRidder schreef op 26 augustus 2019 13:37:


    Gala is van beroep sprookjesverteller bij de Efteling.

    Er was eens een klein, nietig en ontzettend lelijk zwart riddertje..
    Ps:dit sprookje loopt niet goed af voor het riddertje...!!!

    Riddertje woont al zijn hele leventje in de Efteling
  6. forum rang 5 Gala-diner 27 augustus 2019 14:29
    quote:

    Alex69 schreef op 27 augustus 2019 12:34:


    @ Gala. Haal jij dat blok op 6,70 even weg zodat we door kunnen?

    Nee joh, kan ik nog spotgoedkoop bijkopen ;-)
    Wel jammer dat iemand anders 13.000 stuks in de bied heeft gezet op 6,53...
    Eens kijken wie er gaat winnen vandaag.
    Als ze aan mijn blok gaan knabbelen haal ik hem wel weg, dus doe je best.
  7. forum rang 10 voda 29 augustus 2019 07:51
    Kleiner verlies voor Vivoryon

    FONDS KOERS VERSCHIL VERSCHIL % BEURS
    Vivoryon Therapeutics AG
    6,60 0,00 0,00 % Euronext Amsterdam

    (ABM FN-Dow Jones) Vivoryon , het voormalige Probiodrug, heeft in de eerste zes maanden van 2019 de kosten omlaag gebracht, terwijl de kaspositie steeg. Dit bleek donderdag voorbeurs uit een update van het Duitse biotechbedrijf met een beursnotering in Amsterdam.

    In het eerste halfjaar daalden de kosten. Er werd in de verslagperiode geen omzet behaald. Het nettoverlies daalde van 4,1 miljoen naar 3,1 miljoen euro en operationeel was er ook een verlies van 3,1 miljoen euro.

    De kaspositie, die eind 2018 stond op 3,8 miljoen euro, was na een half jaar gestegen tot 8,0 miljoen euro. Vivoryon haalde met een private plaatsing netto 7,6 miljoen euro op.

    CEO Ulrich Dauer zei in een toelichting te blijven focussen op de de kaspositie om voldoende kapitaal te hebben om de gestelde doelen ook daadwerkelijk te kunnen halen.

    Door: ABM Financial News.
    info@abmfn.nl
    Redactie: +31(0)20 26 28 999

    © Copyright ABM Financial News B.V. All rights reserved.
  8. forum rang 5 Gala-diner 29 augustus 2019 08:58
    Vivoryon Therapeutics Reports Financial Results for H1 2019
    and Corporate Update


    Conference call and webcast in English at 3:00 pm CEST / 09:00 am EST
    Successful private placement of EUR 8.2 million
    Strategic collaboration with MorphoSys announced in July for the development of QPCTL technology in immuno-oncology


    HALLE (SAALE), Germany, 29 August 2019 - Vivoryon Therapeutics AG (Euronext Amsterdam: VVY), today announced its financial results for the first six months of 2019 ending June 30. The full interim report is available on the company website (https://www.vivoryon.com/investors-news/financial-information/).


    KEY HIGHLIGHTS

    Probiodrug AG and the Alzheimer's Disease Cooperative Study (ADCS) received USD 15 million grant from NIH for US-based Phase 2b trial
    Probiodrug raised EUR 8.2 million from investors in successful private placement of new shares
    Probiodrug AG became Vivoryon Therapeutics AG
    Shareholder's meeting resolved for a capital increase to be implemented before the end of the year 2019
    Vivoryon entered into a collaboration with University of Kiel to select candidates from QPCTL inhibitor portfolio

    POST PERIOD HIGHLIGHTS
    Business development efforts in the first half year 2019 led to the announcement of a strategic collaboration with MorphoSys in July for the development of QPCTL technology in immuno-oncology. Vivoryon entered into an exclusive Option Agreement for an up to EUR 15 million equity commitment.



    Comment from Dr. Ulrich Dauer, Chief Executive Officer of Vivoryon Therapeutics:

    The last six months stand as a transformative time period for Vivoryon during which the team strategically advanced and repositioned the Company through the achievement of several noteworthy corporate goals including the licensing agreement with MorphoSys for our QPCTL inhibitors in oncology, in addition to the validation of our Alzheimer's Disease program from the NIH. Having collaborated with the management team to redefine our objectives and the most optimal steps to achieve them, we remain well-positioned to reach the next set of corporate and clinical milestones.


    Looking back at the first half of 2019, we strengthened three core elements of the Company: our corporate and financial position, the recognition of our potential in oncology and the validation of our approach in Alzheimer's Disease.


    Starting with the completion of a successful private placement, we enhanced our financial standing and added a consortium of new strategic investors to our shareholder base. On top of this, we rebranded and redefined our position as a company. Our new name, "Vivoryon Therapeutics AG," highlights our strong commitment to developing a treatment for patients suffering from Alzheimer's Disease and emphasizes the fresh perspectives and momentum we aim to leverage to efficiently advance the Company.


    From a pipeline perspective, we have made quantifiable progress in monetizing the opportunity within our approach in immuno-oncology. This was emphasized by our licensing agreement with MorphoSys, which delivered on our promise to combine our unique portfolio of proprietary small molecule QPCTL inhibitors with a leading antibody technology. In addition to this, we also initiated a research collaboration with the University of Kiel to further uncover the therapeutic potential of our QPCTL inhibitors in cellular cancer models.


    In regard to our Alzheimer's program, we received the approval of a USD 15 million NIH grant intended for a US Phase 2b trial, further validating our differentiated therapeutic approach to this detrimental neurodegenerative disease. Our lead candidate, PQ912, stands out from other treatments in the field, as it inhibits the production of the pyroglutamated form of abeta, a neuro- and synaptotoxic driver of Alzheimer's initiation and progression. Our aim is to advance the Phase 2b clinical trial in Europe during the first quarter of 2020.


    As we enter into the second half of the year, we will continue to finalize preparations for the Alzheimer's clinical trial, explore the potential of our unique proprietary position in cancer and identify additional opportunities within our discovery and development pipeline of small molecule therapeutics. With our near-term objective focused on securing the required financial runway to meet these goals, we look forward to connecting with potential investors and partners in the global biotechnology industry and sharing our revitalized vision of leveraging our versatile scientific approach to advance drug candidates in complex and large medical need indications.



    FINANCIAL PERFORMANCE


    KEY FIGURES (ACCORDING TO IFRS)

    In EUR k, unless otherwise stated Jan. - June 2019 Jan. - June 2018 Jan. - Dec. 2018
    Earnings, Financial and Net Assets Position
    Operating loss -3,077 -4,133 -7,698
    Finance income /loss -15 13 -39
    Net loss for the period -3,091 -4,120 -7,737
    Equity (end of the reporting period) 5,636 4,848 1,230
    Equity ratio (end of the reporting period) (in %) 60.8 67.6 30.4
    Balance sheet total (end of the reporting period) 9,269 7,169 4,048
    Cash flows from operating activities (cum.) -3,428 -4,092 -6,994
    Cash flows from operating activities (monthly average) -571 -682 -583
    Cash flows from investing activities -4 471 460
    Cash flows from financing activities 7,644 0 0
    Personnel
    Total number of employees (incl. Board of management) (end of the reporting period) 16 14 14
    Vivoryon Therapeutics-Share
    Loss per share (basic/diluted) (in EUR) -0.31 -0.50 -0.94
    Number of shares issued (end of the reporting period) 12,301 8,208 8,208

    Details of the Financial Results (according to IFRS)

    Net loss

    The operating loss for first half of 2019 was reduced by 26% to EUR 3,077k (H1 2018: EUR 4,133k). This was driven by lower research and development expenses of EUR 1,862k (H1 2018: EUR 2,572k) and lower general and administrative of EUR 1,223k (H1 2018: EUR 1,578k).

    Consequently, net loss was reduced to EUR 3,091k (H1 2018: EUR 4,120k).

    All results are in line with management expectations.


    Cash

    Vivoryon Therapeutics held EUR 7,999k in cash and cash equivalents as of June 30, 2019 (Dec 31, 2018: EUR 3,783k).


    The cash flow from financing activities in amount of EUR 7,644k resulted from the successful private placement of new shares that raised EUR 8,187k in gross proceeds, which were offset by the associated transaction costs of EUR 523k.

  9. forum rang 5 Gala-diner 29 augustus 2019 09:01
    VIVORYON THERAPEUTICS' CURRENT VISION

    With 20+ years of unmatched understanding in identifying protein-modifying enzymes that play a critical role in disease initiation and progression, Vivoryon Therapeutics scientific expertise has facilitated the creation of a discovery and development platform for small molecule therapeutics.

    Having demonstrated success by developing a novel therapeutic in type 2 diabetes, the Company is advancing their lead candidate, PQ912, in Alzheimer's Disease and their entire portfolio of QPCT and QPCTL inhibitors in oncology.



    NEW THERAPEUTIC APPROACH

    PQ912 in Alzheimer's Disease

    PQ912 is a first-in-class inhibitor of the QC enzyme that addresses a very distinct disease pathway and provides a different mode of action in contrast to other available Alzheimer's Disease programs in development. Positive results from a Phase 2a clinical trial published in June 2017 demonstrated a significant improvement in the synaptic function of PQ912-treated Alzheimer's patients versus a control group in addition to measurable improvements in the memory performance of patients treated with PQ912, despite the short treatment time of only twelve weeks.


    The upcoming Phase 2b European, multicenter study, "SAPHIR," will be conducted over 56 weeks on average and will test varying doses of PQ912. Trial initiation is anticipated in the first quarter of 2020 with the topline results expected in the second half of 2022.


    The SAPHIR clinical trial in Europe is led by Professor Philip Scheltens, Director of the Alzheimer Center VU University Medical Center Amsterdam, NL. A second complementary trial, so called US trial, is in the planning phase and will be run by Professor Howard Feldman, Director of Alzheimer's Disease Cooperative Study (ADCS), in San Diego, USA. The National Institutes of Health (NIH) is funding, in part, the US Phase 2b core program with an NIH Research Project grant expected to total of USD 15 million over four years.


    QPCTL Inhibitors in Oncology and Beyond
    Recently published results as well as internal research have shown that the Glutaminyl-peptide cyclotransferase-like (QPCTL) is an interesting therapeutic target to silence the "do not eat me" signal provided by the interaction of CD47 (expressed on cancer cells), with the protein SIRP-alpha (expressed on macrophages and other myeloid cells). Tumor immunotherapy that targets this interaction is a current focus of innovation in cancer drug development. Combining a therapeutic tumor-targeted antibody of choice with the inhibition of the CD47/SIRP-alpha interaction is expected to lead to significant therapeutic improvements. By possessing the broadest portfolio of small molecule QPCTL inhibitors and the clinically most advanced compounds in that field, Vivoryon is uniquely positioned to address this attractive target in immuno-oncology. QPCTL inhibitors are expected to have considerable therapeutic advantages compared to antibody approaches that are currently explored in clinical studies to silence the CD47/SIRP-alpha interactions.


    Based on Vivoryon Therapeutics' data, PQ912 could be advanced into clinical Phase I studies in cancer. In addition, the Company entered into an exclusive Option Agreement with MorphoSys on small molecule inhibitors of QPCTL, silencing the CD47-SIRP alpha signaling in immuno-oncology. Vivoryon Therapeutics owns a broader set of highly promising QPCTL inhibitor compounds in advanced preclinical stages of development.


    Within the collaboration of the University of Kiel, Vivoryon Therapeutics will also fund focused research with the clear goal of further validating its QPCTL inhibitors in cellular cancer models. The Company's highly active compounds will be tested individually and in combination with therapeutic antibodies.



    CONFERENCE CALL
    Vivoryon Therapeutics will host a conference call and webcast open to the public today, August 29, 2019 at 3:00 pm CEST / 09:00 am EST; the presentation will also be available on the company website. The conference will be held in English. A question & Answer session will follow the presentation of the Half year results.

    To participate in the conference call, please call one of the following numbers 10 minutes prior to commencement.

    A live webcast and slides will be made available at: www.vivoryon.com/investors-news/finan...
  10. Inhoudelijk 29 augustus 2019 09:17
    Op zich mooie cijfers voor dit bedrijf dat als "geneesmiddelenonderzoeker" al jaren een nette cash burn laat zien. Geen extreme gekkigheden maar keurig met de investeringen weet om te gaan.

    Alzheimer, een extreem moeilijk te bestrijden ziekte waarbij 'de grote spelers' al eerder de handdoek in de ring hebben gegooid en Vivoryon in mooie onderbouwde stappen rustig door gaat met een, althans volgens mij, succesvol onderscheidend traject. Als Vivoryon haar doelen behaalt dan is dat veel belovend voor deze ziekte die 10-tallen miljoenen wereldwijd raakt, Interresant bedrijf om te volgen en in te investeren voor de lange termijn. Ook fijn dat men niet een beschermingswal opwerpt als bij Kiadis. Doel moet zijn een succesvol medicijn en niet een beschermde onderneming (ethisch bezien dan) en een eventuele overname 'mag gewoon plaats vinden' om dat doel te bereiken
3.114 Posts
Pagina: «« 1 ... 149 150 151 152 153 ... 156 »» | Laatste |Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

VIVORYON THERAPEUT Meer »

Koers 3,985   Verschil -0,04 (-0,99%)
Laag 3,920   Volume 35.845
Hoog 4,100   Gem. Volume 73.384
29 mei 2020 17:29
label premium

Probiodrug: Bodem van de kas in zicht

Het laatste advies leest u als IEX Premium-lid

Inloggen Ontdek Premium

Gerelateerde Video's

  1. video thumbnail

    Arend Jan Kamp over Probiodrug

    11 januari 2018 16:25 - Vimeo

 
Quotedata: Amsterdam realtime by Euronext, other realtime by Cboe Europe Ltd.   US stocks: by NYSE & Cboe BZX Exchange, 15min delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by VWD Group Crypto data by Crypto Compare